These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8271281)

  • 1. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
    Cole DJ; Sanda MG; Yang JC; Schwartzentruber DJ; Weber J; Ettinghausen SE; Pockaj BA; Kim HI; Levin RD; Pogrebniak HW
    J Natl Cancer Inst; 1994 Jan; 86(1):39-45. PubMed ID: 8271281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study.
    Sanda MG; Yang JC; Topalian SL; Groves ES; Childs A; Belfort R; de Smet MD; Schwartzentruber DJ; White DE; Lotze MT
    J Clin Oncol; 1992 Oct; 10(10):1643-9. PubMed ID: 1403042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.
    Bukowski RM; Budd GT; Gibbons JA; Bauer RJ; Childs A; Antal J; Finke J; Tuason L; Lorenzi V; McLain D
    J Clin Oncol; 1994 Jan; 12(1):97-106. PubMed ID: 8270990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
    Minasian LM; Yao TJ; Steffens TA; Scheinberg DA; Williams L; Riedel E; Houghton AN; Chapman PB
    Cancer; 1995 May; 75(9):2251-7. PubMed ID: 7536122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy.
    Zamkoff KW; Hudson J; Groves ES; Childs A; Konrad M; Rudolph AR
    J Immunother (1991); 1992 Feb; 11(2):103-10. PubMed ID: 1571332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.
    Redman BG; Flaherty L; Chou TH; Kraut M; Martino S; Simon M; Valdivieso M; Groves E
    J Immunother (1991); 1992 Jul; 12(1):50-4. PubMed ID: 1637782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.
    Rifkin RM; Hersh EM; Salmon SE
    Behring Inst Mitt; 1988 Aug; (83):125-33. PubMed ID: 3071327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils.
    Cairo MS; Christensen R; Sender LS; Ellis R; Rosenthal J; van de Ven C; Worcester C; Agosti JM
    Blood; 1995 Oct; 86(7):2509-15. PubMed ID: 7670096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.
    Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
    J Clin Oncol; 1989 Feb; 7(2):159-67. PubMed ID: 2644395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.
    Jakubowski AA; Bajorin DF; Templeton MA; Chapman PB; Cody BV; Thaler H; Tao Y; Filippa DA; Williams L; Sherman ML; Garnick MB; Houghton AN
    Clin Cancer Res; 1996 Feb; 2(2):295-302. PubMed ID: 9816172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma.
    Momin FA; Zalupski M; Heilbrun LK; Flaherty L; Fyfe G; Baker LH; Redman BG
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):224-8. PubMed ID: 7834122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor.
    Bretti S; Gilleece MH; Kamthan A; Fitzsimmons L; Hicks F; Rowlands M; Bishop P; Picardo AM; Dexter TM; Scarffe JH
    Eur J Cancer; 1996 Jun; 32A(7):1171-8. PubMed ID: 8758249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.
    Steward WP; Scarffe JH; Austin R; Bonnem E; Thatcher N; Morgenstern G; Crowther D
    Br J Cancer; 1989 Jan; 59(1):142-5. PubMed ID: 2667607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.
    Lieschke GJ; Maher D; Cebon J; O'Connor M; Green M; Sheridan W; Boyd A; Rallings M; Bonnem E; Metcalf D
    Ann Intern Med; 1989 Mar; 110(5):357-64. PubMed ID: 2644886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
    Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
    J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
    Brandt SJ; Peters WP; Atwater SK; Kurtzberg J; Borowitz MJ; Jones RB; Shpall EJ; Bast RC; Gilbert CJ; Oette DH
    N Engl J Med; 1988 Apr; 318(14):869-76. PubMed ID: 3281007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.